Venetoclax ex vivo functional profiling predicts improved progression-free survival

Blood Cancer J. 2022 Aug 4;12(8):115. doi: 10.1038/s41408-022-00710-9.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols
  • Bridged Bicyclo Compounds, Heterocyclic* / pharmacology
  • Bridged Bicyclo Compounds, Heterocyclic* / therapeutic use
  • Humans
  • Progression-Free Survival
  • Proto-Oncogene Proteins c-bcl-2
  • Sulfonamides* / therapeutic use

Substances

  • Bridged Bicyclo Compounds, Heterocyclic
  • Proto-Oncogene Proteins c-bcl-2
  • Sulfonamides
  • venetoclax